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IMPORTANCE Biomarkers that are predictive of outcomes in individuals at risk of psychosis
would facilitate individualized prognosis and stratification strategies.
OBJECTIVE To investigate whether proteomic biomarkers may aid prediction of transition to
psychotic disorder in the clinical high-risk (CHR) state and adolescent psychotic experiences
(PEs) in the general population.
DESIGN, SETTING, AND PARTICIPANTS This diagnostic study comprised 2 case-control studies
nested within the European Network of National Schizophrenia Networks Studying
Gene-Environment Interactions (EU-GEI) and the Avon Longitudinal Study of Parents and
Children (ALSPAC). EU-GEI is an international multisite prospective study of participants at
CHR referred from local mental health services. ALSPAC is a United Kingdom–based general
population birth cohort. Included were EU-GEI participants whomet CHR criteria at baseline
and ALSPAC participants who did not report PEs at age 12 years. Data were analyzed from
September 2018 to April 2020.
MAIN OUTCOMES ANDMEASURES In EU-GEI, transition status was assessed by the
Comprehensive Assessment of At-Risk Mental States or contact with clinical services. In
ALSPAC, PEs at age 18 years were assessed using the Psychosis-Like Symptoms Interview.
Proteomic data were obtained frommass spectrometry of baseline plasma samples in EU-GEI
and plasma samples at age 12 years in ALSPAC. Support vector machine learning algorithms
were used to develop predictive models.
RESULTS The EU-GEI subsample (133 participants at CHR (mean [SD] age, 22.6 [4.5] years; 68
[51.1%] male) comprised 49 (36.8%) who developed psychosis and 84 (63.2%) who did not.
Amodel based on baseline clinical and proteomic data demonstrated excellent performance
for prediction of transition outcome (area under the receiver operating characteristic curve
[AUC], 0.95; positive predictive value [PPV], 75.0%; and negative predictive value [NPV],
98.6%). Functional analysis of differentially expressed proteins implicated the complement
and coagulation cascade. Amodel based on the 10most predictive proteins accurately
predicted transition status in training (AUC, 0.99; PPV, 76.9%; and NPV, 100%) and test
(AUC, 0.92; PPV, 81.8%; and NPV, 96.8%) data. The ALSPAC subsample (121 participants
from the general population with plasma samples available at age 12 years (61 [50.4%]male)
comprised 55 participants (45.5%) with PEs at age 18 years and 61 (50.4%) without PEs at
age 18 years. A model using proteomic data at age 12 years predicted PEs at age 18 years, with
an AUC of 0.74 (PPV, 67.8%; and NPV, 75.8%).
CONCLUSIONS AND RELEVANCE In individuals at risk of psychosis, proteomic biomarkers may
contribute to individualized prognosis and stratification strategies. These findings implicate
early dysregulation of the complement and coagulation cascade in the development of
psychosis outcomes.
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E arly detection of psychosis may improve clinicaloutcomes.1Clinicalhigh-risk (CHR)criteria2enable iden-tification of vulnerable groups with 3-year transition
rates to first-episode psychosis (FEP) of 16% to 35%.3 How-
ever, it is difficult to predict outcomes individually. Previous
studies have also characterized an extended psychosis phe-
notype that includes individuals with psychotic experiences
(PEs).4 These subthreshold symptoms are associated with an
increased risk of psychotic and nonpsychotic disorders5 and
reduced global functioning.6
Biomarkers may augment prognosis and stratification
strategies.7 We aimed to compare plasma protein expression
in individuals at CHR who do and do not develop psychosis
and to developmodels incorporating proteomic data for indi-
vidualizedpredictionof transitiontoFEP.Thisstudyalsoaimed
to apply similar methods for prediction of PEs in a general
population sample.
Methods
Ethical approval for this diagnostic study was granted by the
RoyalCollegeof Surgeons in Ireland.Ethics committeesofpar-
ticipating sites granted approval for the EuropeanNetwork of
National Schizophrenia Networks Studying Gene-Environ-
mentInteractions(EU-GEI).Approvalwasalsoobtainedfromthe
Avon Longitudinal Study of Parents and Children (ALSPAC)
Ethics and Law Committee and local research ethics commit-
tees. Informed consent for collection of biological sampleswas
obtained in accordance with the Human Tissue Act 2004.8 In-
formedconsent foruseofquestionnaire andclinicdatawasob-
tained following recommendations of the ALSPAC Ethics and
LawCommittee at the time.
Study 1: CHR Sample
Participants and Study Design
EU-GEI study includes a prospective cohort of 344 partici-
pants at CHR recruited across 11 international sites.9,10 Indi-
vidualswithCHR symptomswhowere referred by localmen-
tal health serviceswere eligible to participate if theymetCHR
criteria according to the Comprehensive Assessment of At-
Risk Mental States11 (CAARMS) and provided written in-
formed consent. Exclusion criteria were current or past psy-
chotic disorder, symptomsexplainedby amedical disorder or
drug or alcohol use, and IQ less than 60.
Plasma sampleswereobtainedat baseline, and clinical as-
sessments were performed at baseline, 12 months, and 24
months.After 24months, or if a face-to-face interviewwasnot
possible, attemptsweremade to confirm transition status via
the clinical team or records. Assessors were not systemati-
cally blinded to transition status because, in somecases, clini-
cal services contacted the research team in advance to advise
that transitionhadoccurred.Accrualbegan inSeptember2010.
The last baseline assessment was performed in July 2015.
The present investigation comprised a nested case-
control study comparingplasmaproteins fromparticipants at
CHR who transitioned to psychosis on follow-up (CHR-T)
(n = 49) with a control group of randomly selected partici-
pantswhodid not (CHR-NT) (n = 84) (Figure 1). Based onpre-
vious experience,12 the experiment was limited to this num-
ber to ensure optimal technical performance across mass
spectrometry runs.
Outcome and Clinical Measures
Transition was defined as the onset of nonorganic psychotic
disorder as assessed either by CAARMS interview11 or by con-
tact with the clinical teamor review of clinical records. Sixty-
five of 344 participants at CHR (18.9%) developed psychosis
on follow-up, 57 within 24 months and 8 after 24 months.
Baseline clinical measures were recorded. These in-
cluded age, sex, body mass index (BMI; calculated as weight
inkilogramsdividedbyheight inmeters squared),yearsofedu-
cation,GeneralAssessmentofFunctioning (GAF) subscales for
symptoms and disability,13,14 the Scale for the Assessment of
NegativeSymptoms (SANS),15 theBriefPsychiatricRatingScale
(BPRS),16 and theMontgomery-ÅsbergDepressionRatingScale
(MADRS).17
Sample Preparation, Proteomics, Validation, and Replication
Laboratory procedures were conducted blind to case-control
status. Protein depletion, digestion, and peptide purification
Key Points
Question Can plasma proteomic biomarkers aid prediction of
transition to psychotic disorder in people at clinical high risk (CHR)
of psychosis and adolescent psychotic experiences in the general
population?
Findings In this diagnostic study of 133 individuals at CHR in
EU-GEI and 121 individuals from the general population in ALSPAC,
models were developed based on baseline proteomic data, with
excellent predictive performance for transition to psychotic
disorder in individuals at CHR. In a general population sample,
models based on proteomic data at age 12 years had fair predictive
performance for psychotic experiences at age 18 years.
Meaning Predictive models based on proteomic biomarkers may
contribute to personalized prognosis and stratification strategies
in individuals at risk of psychosis.
Figure 1. Derivation of Participants Included in the Initial EU-GEIMass
Spectrometry Experiment and Their Provision of Plasma Samples
344 Participants at CHR recruited
65 CHR-T 279 CHR-NT
49 CHR-T analyzed 84 CHR-NT analyzed
56 Excluded
56 Did not provide sample
139 Random subsample
not selected
16 Excluded
14 Did not provide sample
2 Sample not available at
time of experiment
CHR indicates clinical high risk; CHR-NT, participants at clinical high risk who did
not transition to psychosis; CHR-T, participants at clinical high risk who
transitioned to first-episode psychosis; and EU-GEI, European Network of
National Schizophrenia Networks Studying Gene-Environment Interactions.
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were performed using baseline plasma samples. Discovery-
basedproteomicmethodswereused.12 Briefly, 5μL fromeach
prepared sample was injected on a Q Exactive (Thermo Sci-
entific)mass spectrometer operated indata-dependent acqui-
sition mode for label-free liquid chromatography mass
spectrometry12,18-20 (eMethods in Supplement 1 and eAppen-
dix in Supplement 2).
Nine proteins in plasma samples from the same partici-
pants at CHR described above (Figure 1) were assessed using
enzyme-linked immunosorbentassay (ELISA).Detailsareavail-
able in eMethods in Supplement 1.
In aneffort to reproduceour findings,weconductedapar-
tial replicationof the initialmass spectrometry experiment by
analyzing baseline plasma samples from49CHR-T cases (2 of
these casesweredifferent from the initial experiment) and an
entirely new group of 86 CHR-NT control cases. Details are
available in eMethods in Supplement 1.
Study 2: General Population Sample
Participants and Study Design
TheALSPAC isaprospectivebirthcohort.21-23 Pregnantwomen
in Avon, United Kingdom, with delivery dates between April
1, 1991, andDecember31, 1992,were invited toparticipate, and
14 541 pregnancies were enrolled. When the oldest children
were approximately age 7 years, an attempt wasmade to bol-
ster the samplewith childrenwho did not join originally. The
sample size for analyses using data from age 7 years is 15 454
pregnancies (14901 children alive at 1 year).
Plasmasamplesobtainedat age 12years fromALSPACpar-
ticipantswhodidordidnot reportPEsat age 18yearswerepre-
viously investigated.12,20 In data-independent acquisition
analyses focusedonproteinsof thecomplementpathway, sev-
eral proteins were differentially expressed. Herein, we per-
formeddata-dependentacquisitionanalyses (rather thandata-
independent acquisition) in this sample to achieve broader
proteome coverage.
Outcome, Sample Preparation, and Proteomics
Psychotic experiences were assessed in participants at age 12
years and age 18 years using the Psychosis-Like Symptoms
Interview4 and were rated as not present, suspected, or defi-
nite. Of 4060 participants assessed at both time points, 190
(4.7%) had suspected or definite PEs at age 18 years but not at
age 12 years.4 The present studywas based on a subsample of
case participants (who did not report PEs at age 12 years but
reported at least 1 definite PE at age 18 years) and randomly
selected control participants (whodidnot report PEs at either
age 12 years or age 18 years).
Plasma samples at age 12 years were prepared as previ-
ously described.12 Data-dependent acquisition proteomic
analyses were performed as for study 1.
Data and Statistical Analyses
Datawere analyzed fromSeptember 2018 toApril 2020.Clini-
cal datawere tested for differences using the 2-sided t test for
continuous variables and χ2 test for categorical variables in
SPSS, version 25 (IBM). P values were corrected for multiple
comparisonsusing theBenjamini-Hochbergprocedure24with
a 5% false discovery rate (FDR). The threshold for statistical
significance was FDR-corrected P < .05.
Label-freequantificationwasperformedinMaxQuant,ver-
sion 1.5.2.8 (Max Planck Institute of Biochemistry).25,26 Pro-
teins identifiedwith at least 2 peptides (1 uniquely assignable
to the protein) and quantified in more than 80% of samples
were taken forward for analysis and log2 transformed. Miss-
ingvalueswere imputedusing imputeLCMD(version2.0)27 in
RStudio.28 Label-free quantificationvalueswere converted to
z scores and winsorized within ±3 z.
Analysis of covariance was performed in Stata, version
15 (StataCorp LLC), comparing the mean label-free quantifi-
cation for each protein in cases and controls. Covariates
included age, sex, BMI, and years of education in study 1
and sex, BMI at age 12 years, and maternal social class in
study 2. P values were corrected for multiple comparisons
with a 5% FDR.
PredictiveModels
Neurominer, version 1.0, for MatLab 2018a (MathWorks Inc)
was used to develop support vector machine (SVM) models
(eMethods in Supplement 1). Thedevelopment of eachmodel
is summarized in eTable 1 in Supplement 1.
Models 1a-c: Predicting Transition Using Clinical and Proteomic Data
First, we developed amodel predicting transition using clini-
cal and proteomic data together (model 1a). eTable 2 in
Supplement 1 lists the included clinical features. Geographi-
cal generalizability was incorporated using leave-site-out
cross-validation (eMethods in Supplement 1) as recom-
mended for multisite consortia.29 To assess the relative con-
tribution of clinical and proteomic data, we next developed
models using the same cross-validation and training frame-
work but based on clinical (model 1b) and proteomic (model
1c) features separately.
Model 2a and b: ParsimoniousModel
We sought to generate a parsimoniousmodel based on the 10
highest-weighted proteomic predictors and internally vali-
date thismodel in unseendata (eFigure 1 in Supplement 1). As
the largest site, London, United Kingdom, was chosen as the
test site, and data for these participants were held out.
To derive the 10 highest-weighted proteins, a model
(model 2a) was generated using proteomic data from all
sites except London (n = 30 for CHR-T and n = 50 for CHR-
NT). A reduced model was then developed based solely on
data for these 10 proteins in the non-London data set
(model 2b) and then tested in the held-out London data
(n = 19 for CHR-T and n = 34 for CHR-NT). Both models used
leave-site-out cross-validation.
Model 3: Replication
Becauseofdifferences inprotein identifications, itwasnotpos-
sible to applymodels 1a-c and 2a-b to the replication data set.
We instead sought to replicate our initial findings byperform-
ing a seconddiscovery analysis, generating anewmodel (with
leave-site-out cross-validation) predicting transitionbasedon
clinical and proteomic data in the replication data set.
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Model 4: Predicting PEs Using Proteomic Data
We developed a model predicting PEs at age 18 years in the
ALSPAC based on proteomic data at age 12 years. Repeated
nested cross-validation with 5 inner folds and 5 outer folds
was used.
Supplementary Analyses
Several supplementary analyses (eMethods in Supplement 1)
were performed. These included the following: the develop-
mentofamodelpredicting transition inEU-GEIbasedonELISA
data (model S1), the development of amodel predicting func-
tional outcome in EU-GEI (GAF disability subscale score ≤60
[poor functional outcome] vs >60 [good functional outcome]
at 24months)basedonclinical andproteomicdata (model S2),
investigation of potential EU-GEI site associations for clinical
and proteomic data, and the development of multivariate-
corrected versions of SVM models whereby the variance as-
sociatedwithmultiple covariates was extracted using princi-
pal components analysis.
Results
Study 1: CHR Sample
Of 344 participants at CHR who were recruited, 152 (44.2%)
attended face-to-face interviewsat 12months and 105 (30.5%)
at 24months. Baseline characteristics of participantswhodid
or did not attend at least 1 follow-up interview are compared
in eTable 3 in Supplement 1. After FDR correction, partici-
pants who attended interviews had a mean of 1 more year of
education and a lower mean SANS total global score than
those who did not attend interviews but were otherwise
comparable.
The subsample for the initial experiment comprised 133
(49CHR-T and84CHR-NT) participantswith baseline plasma
samples available, of whom 49 (36.8%) developed psychosis
(Figure 1). Themean (SD) ageof theparticipantswas 22.6 (4.5)
years; 68 participants (51.1%) were male. After FDR correc-
tion,participants included in thesubsamplehadahighermean
SANS total composite, SANS total global, andBPRS total scores
than nonincluded participants but were otherwise compa-
rable on baseline characteristics (eTable 4 in Supplement 1).
Subsample characteristics are listed in Table 1. After FDR
correction, therewereno statistically significant groupdiffer-
ences for CHR-T vs CHR-NT based on baseline characteris-
tics. Themedian duration frombaseline to transitionwas 219
days (interquartile range, 424 days). The CHR-T participants
had lower mean functional outcome scores at 2 years com-
paredwith CHR-NT participants (mean GAF symptoms score
at 2 years, 42.3 in CHR-T vs 62.2 in CHR-NT; FDR-corrected
P < .007; mean GAF disability score at 2 years, 44.7 in CHR-T
vs 64.5 in CHR-NT; FDR-corrected P < .007).
Differential Expression
Of 345 proteins identified, 166 were quantified in more than
80%ofplasma samples. Therewasnominally statistically sig-
nificant (P < .05)differential expressionof56proteins inCHR-T
vs CHR-NT, of which 35 remained statistically significant af-
ter FDR correction (eTables 5 and 6 in Supplement 1). eFig-
ure2 inSupplement 1 showsa functionalassociationnetwork30
for these proteins, and eTable 7 in Supplement 1 lists protein-
protein interactions. On functional enrichment analysis, the
topmost implicatedpathwaywas the complement and coagu-
lation cascade (eTable 8 in Supplement 1).
Model 1a: Predicting Transition Using Clinical and Proteomic Data
AnSVMmodelpredicted transitionstatusbasedonclinical and
proteomic features (model 1a),withexcellentperformance(area
under the receiver operating characteristic curve [AUC], 0.95;
[P < .001]; sensitivity, 98.0%; specificity, 81.0%; positive pre-
dictivevalue[PPV],75.0%;andnegativepredictivevalue[NPV],
98.6%). Performance metrics are listed in Table 2. Figure 2A
showsthemeanalgorithmscoresandpredictedoutcomesstrati-
fiedbysite.Thereceiveroperatingcharacteristiccurve is shown
inFigure2B.Table3 lists the 10%highest-weighted featuresac-
cording to themeanfeatureweight.Forexample, the5highest-
ranked predictive featureswere alpha-2-macroglobulin (A2M)
(mean weight, −0.330), immunoglobulin heavy constant mu
(IGHM)(meanweight,−0.256),C4b-bindingproteinalphachain
(C4BPA) (meanweight, −0.161), complement component 8 al-
phachain (C8A) (meanweight,0.158), andphospholipid trans-
fer protein (PLTP) (meanweight, −0.146).
Model 1b and 1c: Clinical and Proteomic Data
The clinical model (model 1b) demonstrated poor predictive
performance (AUC, 0.48; P = .63). These results are summa-
rized in Table 2 and eFigure 3 in Supplement 1. For example,
sensitivity was 46.9%, specificity was 53.6%, PPVwas 37.1%,
and NPV was 63.4%.
The proteomic model (model 1c) demonstrated excellent
predictiveperformance (AUC,0.96;P < .001).These results are
summarized in Table 2 and eFigure 4 in Supplement 1. For ex-
ample, sensitivity was 100%, specificity was 84.5%, PPVwas
79.0%, and NPV was 100%.
Model 2a and b: ParsimoniousModel
The AUC for the model based on proteomic data from all sites
except London (model 2a) was 0.94 (P < .001) (Table 2 and
eFigure 5 in Supplement 1). The 10 highest-weighted features
were alpha-2-macroglobulin (A2M), immunoglobulin heavy
constant mu (IGHM), C4b-binding protein alpha chain
(C4BPA), vitaminK–dependentprotein S, fibulin 1, transthyre-
tin,N-acetylmuramoyl-L-alanine amidase, vitamin D–binding
protein, clusterin, and complement component 6 (C6).
A reduced model based solely on these 10 most predic-
tive proteins was developed using data from all sites except
London (model 2b), with an AUC of 0.99 (P < .001), sensitiv-
ity of 100%, specificity of 82.0%, PPV of 76.9%, and NPV of
100%) (Table2andeFigure6 inSupplement 1).Thismodelpre-
dicted transition status in the held-out London data, with an
AUCof0.92, sensitivity of 94.7%, specificity of 88.2%, PPVof
81.8%, and NPV of 96.8% (Table 2).
ELISA Validation
AfterFDRcorrection,2proteinsassessedbyELISAshowedsta-
tistically significant mean differences between CHR-T and
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Table 1. Sample Characteristics for CHR-T and CHR-NT Groups in the Initial Experiment
Variable
No. (%)
t or χ2
Statistic P value
Corrected
P value
(FDR 5%)
Missing data
(n = 133)a
CHR-T
(n = 49)
CHR-NT
(n = 84)
Baseline age, mean (SD), y 0 22.2 (5.0) 22.9 (4.2) −0.824 .41 .78
Sex 0
Male 26 (53.1) 42 (50.0)
0.116 .73 .91
Female 23 (46.9) 42 (50.0)
Baseline body mass index, mean
(SD)
20 (15.0) 24.5 (4.5) 24.4 (6.1) 0.116 .91 .91
Baseline years of education,
mean (SD)
14 (10.5) 14.1 (3.4) 14.4 (3.0) −0.625 .53 .79
Race/ethnicity 0
White 33 (67.3) 58 (69.0)
2.370 .31 .65Black 8 (16.3) 7 (8.3)
Other 8 (16.3) 19 (22.6)
Ever used cannabis 3 (2.3)
Yes 36 (73.5) 65 (77.4)
0.051 .82 .91No 11 (22.4) 18 (21.4)
Not known 2 (4.1) 1 (1.2)
Baseline cannabis use 29 (21.8)
Yes 15 (30.6) 26 (31.0)
0.030 .86 .91No 22 (44.9) 41 (48.8)
Not known 12 (24.5) 17 (20.2)
Baseline tobacco useb 14 (10.5)
Yes 21 (42.9) 43 (51.2)
0.373 .54 .79No 21 (42.9) 34 (40.5)
Not known 7 (14.3) 7 (8.3)
Baseline alcohol usec 3 (2.3)
Yes 35 (71.4) 58 (69.0)
0.071 .79 .91No 13 (26.5) 24 (28.6)
Not known 1 (2.0) 2 (2.4)
Baseline medication use 31 (23.3)
Yes 19 (38.8) 32 (38.1)
0.042 .84 .91
Antidepressant 13 24
Antipsychotic 9 6
Hypnotic 2 6
Other 3 13
No 20 (40.8) 31 (36.9)
Not known 10 (20.4) 21 (25.0)
Baseline, mean (SD)
GAF symptoms score 12 (9.0) 52.4 (10.3) 56.0 (10.0) −1.906 .06 .19
GAF disability score 5 (3.8) 52.3 (12.4) 54.8 (11.3) −1.148 .25 .60
SANS total composite score 19 (14.3) 20.9 (14.0) 16.2 (11.6) 1.903 .06 .19
SANS total global score 11 (8.3) 6.6 (4.1) 5.8 (3.7) 1.158 .25 .60
BPRS total score 10 (7.5) 49.1 (11.5) 44.2 (10.2) 2.452 .02 .08
MADRS total score 7 (5.3) 20.3 (10.4) 19.2 (9.2) 0.657 .51 .79
GAF symptoms score at 2 y,
mean (SD)d
62 (46.6) 42.3 (13.2) 62.2 (10.3) −7.125 <.001 <.007
GAF disability score at 2 y,
mean (SD)e
54 (40.6) 44.7 (9.1) 64.5 (12.8) −8.024 <.001 <.007
GAF disability score at 2 y,
dichotomous outcomef
54 (40.6)
Poor functioning 29 (59.2) 18 (21.4)
27.734 <.001 <.007Good functioning 1 (2.0) 31 (36.9)
Not known 19 (38.8) 35 (41.7)
Abbreviations: CHR-NT, participants
at clinical high risk who did not
transition to psychosis;
CHR-T, participants at clinical high risk
who transitioned to first-episode
psychosis; EU-GEI, European
Network of National Schizophrenia
Networks Studying
Gene-Environment Interactions;
FDR, false discovery rate;
GAF, General Assessment of
Functioning; MADRS,
Montgomery-Åsberg Depression
Rating Scale (high score, greater
number and severity of depressive
symptoms; low score, lower number
and severity of depressive
symptoms).
a Missing data were excluded in
hypothesis tests.
bDaily tobacco use for at least 1
month over the previous 12 months.
c At least 12 alcoholic beverages over
the previous 12 months.
dData available for 71 of 133
participants (27 CHR-T and 44
CHR-NT).
e Data available for 79 of 133
participants (30 CHR-T and 49
CHR-NT).
f A GAF disability subscale score of
60 or less indicates poor
functioning, and a score greater
than 60 indicates good functioning.
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CHR-NT.ThesewereA2Mandcomplementcomponent 1r (C1r)
(eTables 9 and 10 in Supplement 1). The A2Mmean in CHR-T
was 1173.1 μg/mL vs 11 501.7 μg/mL in CHR-T (FDR-corrected
P = .02), and the C1r mean in CHR-T was 65008.9 μg/mL vs
52803.9 μg/mL in CHR-NT (FDR-corrected P = .04).
Model 3: Replication
Replication subsample characteristics are listed in eTables 11
and 12 in Supplement 1. Of 485 proteins identified, 119 were
quantified in more than 80% of plasma samples. There was
nominally statistically significant (P < .05)differential expres-
sion of 82 proteins, of which 78 remained statistically signifi-
cant after FDR correction (eTable 13 in Supplement 1).
Model 3 demonstrated excellent performance for predic-
tion of transition in the replication data set (AUC, 0.98
[P < .001]; sensitivity, 98.0%; specificity, 89.5%; PPV, 84.2%;
andNPV, 98.7%) (Table 2 and eFigure 7 in Supplement 1). The
highest-weighted 10%of features are listed in Table 3. For ex-
ample, the 5 highest-ranked predictive features were A2M
(meanweight, −0.286), carboxypeptidase N subunit 2 (mean
weight, 0.210), IGHM (mean weight, −0.193), complement
C1s subcomponent (mean weight, −0.181), and alpha-1-
antichymotrypsin (mean weight, 0.168). Proteins among the
highest-weighted 10%of features in bothmodel 1a andmodel
3 (and weighted in similar directions) included A2M, IGHM,
C4BPA, plasminogen, and C6.
Study 2: General Population Sample
The initial subsamplewas composed of plasma samples from
132 participants (65 case and 67 control samples). Eleven
plasma samples were excluded because of poor protein iden-
tification profiles, resulting in 55 case and66 control samples
from 121 participants (61 [50.4%] male). Case samples were
more likely to be from female participants. There was no evi-
dence for differences in BMI, race/ethnicity, or maternal so-
cial class (eTable 14 in Supplement 1).
Differential Expression
Of 506 proteins identified, 265 were quantified in more than
80%of samples. Therewas nominally statistically significant
(P < .05) differential expression of 40 proteins at age 12 years
(eTable 15 in Supplement 1), of which the following 5 re-
mained statistically significant after FDR correction: C4BPA
(ratio of means in PE vs no PE, 0.77), serum paraoxonase/
arylesterase 1 (ratio of means, 0.80), IGHM (ratio of means,
0.78), inhibin beta chain (ratio of means, 1.31), and clusterin
(ratio of means, 0.92).
Model 4: Predicting PEs Using Proteomic Data
An SVM model using 265 proteomic features from plasma
samples obtained at age 12 years predicted PEs at age 18
years, with an AUC of 0.74 (P < .001), sensitivity of 72.7%,
specificity of 71.2%, PPV of 67.8%, and NPV of 75.8%
(Table 2 and eFigure 8 in Supplement 1). For example, the 5
highest-ranked predictive features were C4BPA (mean
weight, −0.227), serum paraoxonase/arylesterase 1 (mean
weight, −0.180), complement factor H–related protein 1
(mean weight, −0.152), vitamin K–dependent protein S
(mean weight, −0.145), and lysozyme C (mean weight,
−0.142) (Table 3).
Figure 2. Model 1a Predicting Transition to Psychosis Using Clinical and Proteomic Data
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Class predictions for model 1a stratified by EU-GEI study siteA Receiver operating characteristic curve for model 1aB
CHR-NT CHR-T
Site
London, United Kingdom
The Netherlands
Switzerland/Austria
Melbourne, Australia
Denmark/France
Spain/Brazil
CHR-NT classified
CHR-NT misclassified
CHR-T classified
CHR-T misclassified
A, The algorithm score is a decision score used to determine the predicted
outcome class. Herein, a score greater than 0 is assigned as CHR-T, and a score
less than 0 is assigned as CHR-NT. The dashed lines divide the graph into
quadrants according to predicted vs actual outcome (ie, top right is true
positive, bottom left is true negative, top left is false positive, and bottom right
is false negative). B, The dashed line is the line of no discrimination (area under
the receiver operating characteristic curve, 0.5). CHR-NT indicates participants
at clinical high risk who did not transition to psychosis; CHR-T, participants at
clinical high risk who transitioned to first-episode psychosis; and EU-GEI,
European Network of National Schizophrenia Networks Studying
Gene-Environment Interactions.
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Supplementary Analyses
Model S1 used ELISA data to predict transition status in
EU-GEI,with anAUCof0.76 (P < .001). These results are sum-
marized in Table 2 and eFigure 9 in Supplement 1.
Model S2used clinical andproteomic data to predict poor
(GAF disability subscale score ≤60) vs good (>60) functional
outcome at 2 years in EU-GEI, with an AUC of 0.74 (P = .003)
(Table 2 and eFigure 10 in Supplement 1). The 10% highest-
weighted features are listed in eTable 16 in Supplement 1.
There was evidence of differences for the clinical data
between theLondonand theNetherlands sites comparedwith
others (eTable 17, eFigure 11, and eFigure 23 in Supple-
ment 1), likelybecauseofgroupdifferences inage,years inedu-
cation,andBPRSscore (eMethodsandeFigures 13-22 inSupple-
ment 1). There was no strong evidence of systematic site
associations for theproteomicdata (eTable 18, eFigure 12, and
eFigure 24 in Supplement 1).
Performancemetrics ofmultivariate-correctedSVMmod-
els are listed in eTable 19 in Supplement 1. There were gener-
ally slight reductions in AUCs of the corrected models com-
paredwith their uncorrected counterparts (median change in
AUC,0.04; range,0.01-0.10), although in all cases the95%CIs
overlapped.
Table 3. Ten Percent Highest-Weighted Features forModel 1a,
Model 3, andModel 4a
Model/Feature
Mean
weight
Model 1a: EU-GEI clinical and proteomic data, initial experiment, all sites
P01023 Alpha-2-macroglobulin −0.330
P01871 Immunoglobulin heavy constant mu −0.256
P04003 C4b-binding protein alpha chain −0.161
P07357 Complement component 8 alpha chain 0.158
P55058 Phospholipid transfer protein −0.146
O75636 Ficolin 3 −0.145
P02774 Vitamin D–binding protein 0.135
P07225 Vitamin K–dependent protein S −0.132
P43320 Beta-crystallin B2 0.132
P02766 Transthyretin −0.130
P23142 Fibulin 1 0.125
P10909 Clusterin 0.121
P05155 Plasma protease C1 inhibitor −0.114
Sex −0.111
P00747 Plasminogen 0.111
P13671 Complement component 6 0.111
P02747 Complement C1q subcomponent subunit C 0.109
P02753 Retinol-binding protein 4 0.109
Q76LX8 A disintegrin and metalloproteinase with thrombospondin
motifs 13
−0.108
P08697 Alpha-2-antiplasmin −0.106
P19827 Inter-alpha-trypsin inhibitor heavy chain H1 0.105
MADRS: concentration difficulties −0.104
P02489 Alpha-crystallin A chain 0.101
Model 3: EU-GEI clinical and proteomic data, replication experiment, all sites
P01023 Alpha-2-macroglobulin −0.286
P22792 Carboxypeptidase N subunit 2 0.210
P01871 Immunoglobulin heavy constant mu −0.193
P09871 Complement C1s subcomponent −0.181
P01011 Alpha-1-antichymotrypsin 0.168
P00747 Plasminogen 0.163
P08571 Monocyte differentiation antigen CD14 0.161
P10909 Clusterin 0.158
Q16610 Extracellular matrix protein 1 0.157
G3XAM2 Complement factor I 0.140
P04003 C4b-binding protein alpha chain −0.140
P13671 Complement component 6 0.132
P25311 Zinc alpha-2-glycoprotein −0.131
P07359 Platelet glycoprotein Ib alpha chain 0.126
P01031 Complement C5 0.125
O75882 Attractin 0.123
P0DOY3 Immunoglobulin lambda constant 3 −0.120
P15169 Carboxypeptidase N catalytic chain (CPN) 0.115
Model 4: ALSPAC proteomic data
P04003 C4b-binding protein alpha chain −0.227
P27169 Serum paraoxonase/arylesterase 1 −0.180
Q03591 Complement factor H–related protein 1 −0.152
P07225 Vitamin K–dependent protein S −0.145
P61626 Lysozyme C −0.142
(continued)
Table 3. Ten Percent Highest-Weighted Features forModel 1a,
Model 3, andModel 4a (continued)
Model/Feature
Mean
weight
P55103 Inhibin beta C chain 0.139
Q08380 Galectin 3–binding protein 0.132
P24593 Insulinlike growth factor–binding protein 5 0.122
P00746 Complement factor D 0.120
P01019 Angiotensinogen −0.118
P01871 Immunoglobulin heavy constant mu −0.116
O75636 Ficolin 3 0.115
Q9H4A9 Dipeptidase 2 −0.115
P01023 Alpha-2-macroglobulin −0.113
P04275 von Willebrand factor −0.111
Q9NQ79 Cartilage acidic protein 1 0.107
P24592 Insulinlike growth factor–binding protein 6 0.106
P09871 Complement C1s subcomponent −0.105
P10909 Clusterin −0.105
O95497 Pantetheinase 0.105
P02654 Apolipoprotein C-I −0.099
P02679 Fibrinogen gamma chain −0.099
P07358 Complement component C8 beta chain 0.097
Q5T7F0 Neuropilin −0.097
P04040 Catalase 0.094
P43251 Biotinidase 0.094
Abbreviations: ALSPAC, Avon Longitudinal Study of Parents and Children;
BPRS, Brief Psychiatric Rating Scale; EU-GEI, European Network of National
Schizophrenia Networks Studying Gene-Environment Interactions;
MADRS, Montgomery-Åsberg Depression Rating Scale; SANS, Scale for the
Assessment of Negative Symptoms.
a Ranked according to themean feature weight for models selected in
cross-validation inner loop. Proteins are presented with their UniProt
accession number and corresponding protein name.
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Discussion
We described evidence of differential baseline plasma pro-
tein expression in individuals at CHRwhodevelopedpsycho-
sis comparedwith thosewho did not. Machine learning algo-
rithms that incorporatedclinical andproteomicdatawereused
to predict transition outcome (AUC, 0.95). Proteomic fea-
tureswere of greater predictive value than clinical features. A
parsimonious model based on 10 highly predictive proteins
showedexcellentperformance in training (AUC,0.99) and test
(AUC,0.92) data. Furthermore, a predictivemodelwasdevel-
opedusingproteomicdataat age 12years forPEsat age 18years
in a general population sample (AUC, 0.74).
Althoughonly 16% to 35%of individuals at CHR transition
toFEP,3 theCHRstateremainsastrongrisk factor.31Clinicaldata
have previously shown value for prediction of transition,32-37
and the poor performance of the clinical features in our study
doesnot imply that clinicaldata ingeneral areof littleprognos-
tic use. Previous studies have attempted to augment accuracy
usingneuroimaging38-41 andneurocognitive42data, butblood-
based tests have the advantage of greater accessibility. Perkins
et al43 derived a panel of 15 proteins using immunoassays that
distinguishedbetweenCHR-TandCHR-NT,withanAUCof0.88.
Chanet al44used22blood-basedbiomarkers topredict schizo-
phrenia onset,with anAUCof0.82 that increased to0.90with
incorporationof theCAARMSpositivesymptomssubscale.Our
parsimonious model used data for 10 proteins, and, with fur-
thervalidation,maycontribute to individualizedprognosisand
treatment stratification strategies.45
eTable 20 in Supplement 1 summarizes our findings of dif-
ferentialexpressioninCHR-TvsCHR-NTandthepredictedfunc-
tional implications (modeled ineFigure25 inSupplement1).We
found particularly strong evidence for dysregulation of the
complementandcoagulationcascade,previously implicated in
schizophrenia.46-50Similarprocesseshavebeenpreviously im-
plicated in proteomic studies of the development of PEs in the
general population.12,20Changes in thepresentCHRstudy that
were consistentwith results fromthesepreviousPEstudies in-
clude increases in plasminogen, C1r, clusterin, and comple-
ment factor H and decreases in A2M and IGHM. The primary
causesofthesechangesremainunknownbutareconsistentwith
evidence of enhanced inflammatory toneprecedingpsychosis
andothermental disorders43,44,51-55 and schizophrenia risk as-
sociated with genetic variation of complement C4.56
Several complementproteinsemergedas importantpredic-
torsof transition, includingC4BPA,C1r of theantibody-antigen
complex mediated pathway, key regulatory protease comple-
ment factor I, and terminal pathway components C6 and C8A.
Thesearisefromcommonpathwaysorfunctionally interactwith
coagulationproteinsplasminogenandvitaminK–dependentpro-
tein S, supporting hypotheses of coagulation activation in
psychosis.57 Inboth the initial and replicationexperiments, the
most highly weighted predictor of transition was A2M (de-
creased inCHR-TvsCHR-NT), a protease inhibitorwithdiverse
functions, including inhibition of proinflammatory cytokines
such as interleukin 1β58 (consistently elevated in FEP59). A2M
isakeycoagulation inhibitor60andthus links functionally toour
observations of elevated plasminogen inCHR-T. This finding is
intriguing given the evidence that blood-derived plasminogen
is associated with brain inflammation61 and complement
activation.62 In models of multiple sclerosis, blood-brain bar-
rier disruption facilitates transfer of fibrinogen into the brain,
where it is deposited as fibrin, causing local inflammation.63
Given evidence for blood-brain barrier disruption in
psychosis,64 fibrin may be associated with etiopathogenic
mechanisms providing novel therapeutic avenues,65 but this
hypothesis requires further investigation.
Wevalidateddifferential expressionofA2MandC1r using
ELISA. The ELISA-based model (model S1) demonstrated
fair, although reduced, predictive accuracy. This findingmay
reflect reduced sensitivity of ELISA and the inability to accu-
rately quantify specific protein isoforms. Several proteins in
the highest-weighted 10% of features for transition in study 1
were similarly highly weighted for PEs in study 2, including
C4BPA, vitamin K–dependent protein S, A2M, and IGHM
(eTable 21 in Supplement 1 summarizes the directionality of
association of the 10% highest predictors in model 1a, model
3, andmodel4).Thisobservationmaysuggest adegreeof simi-
larity in proteomic changes betweenyoungpeople in the gen-
eral population who develop PEs and help-seeking individu-
als atCHRwhodeveloppsychosis, but thishypothesis requires
confirmation.
Outsideofpsychosis outcomes, several proteomic features
contributedtopredictionoffunctionaloutcome(modelS2).A2M,
IGHM,phospholipid transferprotein,andclusterinwereamong
the 10% highest-weighted predictors. The results of the pres-
entstudyarealso inkeepingwithstudies inbipolardisorderand
depressionreportingdecreasedA2M,IgM,andC4BPA.66At least
some of these proteomic changesmay be common tomultiple
clinicalphenotypes, includingneurodegenerativedisorders,such
as Alzheimer disease.67 Rather than considering such changes
as biomarkers of individual disorders, phenotypic manifesta-
tionsmaybe clinicalmarkers of a variety of overlappingneuro-
immune abnormalities that have their origin in combined
genetic56,68 and environmental69-72 factors.
Limitations
This study has some limitations. First, these models require
validation in independent cohorts to assess generalizability
and real-world applicability. Second, differences in protein
identifications precluded application of models between
studies. However, there are valid reasons not to do so, includ-
ing differences in outcome (psychotic disorder vs PEs) and
age (postpubertal vs peripubertal). Third, data on duration of
follow-up and reasons for dropout were not systematically
collected in EU-GEI, and we were unable to fully assess the
potential implications of these factors. Fourth, the replica-
tion experiment was partial because only 2 CHR-T cases were
different from the initial experiment. Although our findings
were generally replicated, no statement can be made regard-
ing generalizability of model sensitivity. Fifth, participants
were nonfasting, and there were no restrictions on time of
sample collection. Sixth, other factors, such as childhood
adversity, may have contributed to the proteomic changes
that we observed,10,71 but these factors require further study.
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Conclusions
We developed models incorporating proteomic data predict-
ing transition to psychotic disorder in the CHR state. In a
general population sample, several of the same proteins
contributed to prediction of PEs. Further studies are re-
quired to validate these findings, evaluate their causes, and
elucidate tractable targets for prediction and prevention of
psychosis.
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